NO20091691L - Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav - Google Patents

Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav

Info

Publication number
NO20091691L
NO20091691L NO20091691A NO20091691A NO20091691L NO 20091691 L NO20091691 L NO 20091691L NO 20091691 A NO20091691 A NO 20091691A NO 20091691 A NO20091691 A NO 20091691A NO 20091691 L NO20091691 L NO 20091691L
Authority
NO
Norway
Prior art keywords
pth
pegylated
receptor modulators
pth receptor
mammal
Prior art date
Application number
NO20091691A
Other languages
English (en)
Other versions
NO341986B1 (no
Inventor
Patricia Lea Brown-Augsburger
Wayne David Kohn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20091691L publication Critical patent/NO20091691L/no
Publication of NO341986B1 publication Critical patent/NO341986B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)

Abstract

Farmasøytiske sammensetninger og fremgangsmåter er tilveiebrakt for behandling og hindring av bentapsykdommer som inkluderer osteoporose hos pattedyr.
NO20091691A 2006-10-13 2009-04-28 Pegylert PTH som PTH reseptor modulatorer, sammensetninger inneholdende slike og anvendelser derav NO341986B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82938306P 2006-10-13 2006-10-13
PCT/US2007/080367 WO2008048784A1 (en) 2006-10-13 2007-10-04 Pegylated pth as pth receptor modulators and uses thereof

Publications (2)

Publication Number Publication Date
NO20091691L true NO20091691L (no) 2009-05-11
NO341986B1 NO341986B1 (no) 2018-03-12

Family

ID=42828673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091691A NO341986B1 (no) 2006-10-13 2009-04-28 Pegylert PTH som PTH reseptor modulatorer, sammensetninger inneholdende slike og anvendelser derav

Country Status (16)

Country Link
US (1) US7820179B2 (no)
EP (1) EP2084183B1 (no)
JP (1) JP5200027B2 (no)
KR (1) KR101108354B1 (no)
CN (1) CN101522709B (no)
AT (1) ATE469173T1 (no)
AU (1) AU2007313001B2 (no)
BR (1) BRPI0719885B8 (no)
CA (1) CA2672907C (no)
DK (1) DK2084183T3 (no)
EA (1) EA014696B1 (no)
MX (1) MX2009003740A (no)
NO (1) NO341986B1 (no)
PL (1) PL2084183T3 (no)
SI (1) SI2084183T1 (no)
WO (1) WO2008048784A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
IL317744A (en) 2016-03-01 2025-02-01 Ascendis Pharma Bone Diseases As PTH drug agonists
PL3518961T3 (pl) 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
FI3518982T3 (fi) 2016-09-29 2025-02-11 Ascendis Pharma Bone Diseases As Säädellysti vapautuvia PTH-yhdisteitä
RS64440B1 (sr) * 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
EP3790574A4 (en) 2018-05-30 2022-07-13 Purdue Research Foundation TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR
US12403182B2 (en) 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
JPS6360940A (ja) 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
JPH05271279A (ja) * 1991-08-07 1993-10-19 Takeda Chem Ind Ltd ヒト副甲状腺ホルモンムテインおよびその製造法
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5556940A (en) * 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
RU2203286C2 (ru) 1996-08-02 2003-04-27 Нэшнл Рисерч Каунсил ов Кэнэда Аналоги паратиреоидного гормона для лечения остеопороза
SK151599A3 (en) * 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
WO1999018945A1 (en) * 1997-10-14 1999-04-22 Eli Lilly And Company Method of building and maintaining bone
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1093458A4 (en) * 1998-04-15 2001-07-18 Aventis Pharm Prod Inc METHOD FOR THE PRODUCTION OF RESIN-TIED CYCLIC PEPTIDES
US7531621B1 (en) 1998-05-05 2009-05-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. PTH2 receptor selective compounds
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US7022815B1 (en) * 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2003009804A2 (en) 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG-CONJUGATED PTH BZW. PEG-CONJUGATED PTH DERIVATIVE
US7799757B2 (en) * 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
TW533925U (en) * 2002-09-26 2003-05-21 Lee Yeong Ind Co Ltd Improvement of speed-changing transmission mechanism for cutting tools of drill sharpening machine
AU2002359391A1 (en) 2002-11-01 2004-07-29 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
WO2004084918A1 (ja) * 2003-03-25 2004-10-07 Sekisui Chemical Co., Ltd. 皮膚止痒外用組成物
US20040220094A1 (en) * 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1758927A4 (en) 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF

Also Published As

Publication number Publication date
WO2008048784A1 (en) 2008-04-24
EP2084183A1 (en) 2009-08-05
EA014696B1 (ru) 2010-12-30
CN101522709A (zh) 2009-09-02
JP2010506844A (ja) 2010-03-04
ATE469173T1 (de) 2010-06-15
AU2007313001A1 (en) 2008-04-24
KR101108354B1 (ko) 2012-01-25
BRPI0719885B1 (pt) 2018-12-11
AU2007313001B2 (en) 2012-03-22
US20090253630A1 (en) 2009-10-08
BRPI0719885A2 (pt) 2014-04-29
NO341986B1 (no) 2018-03-12
DK2084183T3 (da) 2010-08-16
CA2672907A1 (en) 2008-04-24
BRPI0719885B8 (pt) 2021-05-25
EA200970376A1 (ru) 2009-10-30
MX2009003740A (es) 2009-04-22
EP2084183B1 (en) 2010-05-26
CA2672907C (en) 2013-08-06
US7820179B2 (en) 2010-10-26
JP5200027B2 (ja) 2013-05-15
SI2084183T1 (sl) 2010-09-30
KR20090067168A (ko) 2009-06-24
PL2084183T3 (pl) 2010-10-29
CN101522709B (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
UY30304A1 (es) Moduladores de mglur5 i
DK2084183T3 (da) Pegyleret PTH som PTH-receptormodulatorer og anvendelser deraf
NO20083011L (no) Modulatorer av muskarine receptorer
EP1898827A4 (en) DENTAL RESTORATION SYSTEM AND COMPONENTS
PL2066179T3 (pl) Formulacje zawierające indoksakarb do miejscowego podawania na skórę
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
UY30308A1 (es) Moduladores de mglur5 v
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
DK2059243T3 (da) Buprenorphin-vaffel til lægemiddelsubstitutionsterapi
EP2175800A4 (en) COMPOSITE IMPLANT FOR SURGICAL REPAIR
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
EP1981970A4 (en) TISSUE CONSTRUCTION TISSUE TREATMENT DERIVED FROM A HUMAN EMBRYONIC STEM CELL
UY30307A1 (es) Moduladores de mglur5 vi
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UY30306A1 (es) Moduladores de mglur5 iii
DK2205558T3 (da) Substituterede n-phenylpyrrolidinylmethylpyrrolidinamider og terapeutisk anvendelse deraf som histamin-h3- receptormodulatorer
NO20084006L (no) Modulatorer av muskarinreseptorer
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
UY30305A1 (es) Moduladores de mglur5 iv
UY30309A1 (es) Moduladores de mglur5 ii
EP2127681A4 (en) THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees